ST. LOUIS, Nov 17, 2018 /PRNewswire/ -- DirectBiologics, LLC
announces the acquisition of Paisley Laboratories, LLC. The
mission of these combined research and development companies is to
transform regenerative healing with an emphasis on improved patient
care. Direct Biologics is focused on optimizing the
regenerative potential of its unique technologies as an industry
leader in providing innovative tissue-based technologies for
stimulating regeneration across various applications in
orthopedics, plastic surgery, general surgery, podiatry, and more.
The acquisition of Paisley Laboratories, LLC expands their ability
to develop innovative and revolutionary products based on utilizing
human mesenchymal stem cells.
Currently, in the United
States, over 60 million people have some type of joint or
spine pain and there are approximately 12 million interventional
procedures performed every year. Direct Biologics' goal is to
change the treatment paradigm for this market through clinical and
scientific initiatives. Additionally, Direct Biologics owns a
comprehensive intellectual property portfolio and is developing
products to revolutionize the aesthetics market with technology
that has been scientifically proven to minimize skin aging and
restore hair loss. The global aesthetics market is valued at
$10 Billion and Direct Biologics'
products are applicable in a majority of these 23 million
procedures. Direct Biologics' human stem cell technologies
work with your body by stimulating your cells' inherent
regenerative ability to achieve natural healing. Joe Schmidt, the company's President and
Co-founder, said, "Imagine having the ability to treat arthritis,
skin aging or pain by unleashing the power of regeneration already
present within your own body." Mark Adams, the company's CEO
and Co-founder, said, "This new level of unequaled human cellular
regeneration is about to become a reality because of the disruptive
technologies currently being marketed by Direct Biologics and via
the stem cell technology patents we acquired."
Go to DIRECTBIOLOGICS.COM to learn more.
ABOUT DIRECT BIOLOGICS: Direct Biologics, LLC, headquartered in
St. Louis, MO, is a market-leading
innovator and science-based manufacturer of regenerative medical
products, including a robust line of biologic and kyphoplasty
products. Direct Biologics was created to expand the science
of cutting-edge biologic technologies through research and
commercialization of medical devices and the naturally occurring
proteins from allograft tissue compliant with FDA standards for 361
HCT/P products. Current commercial products include, but are
not limited to, AmnioFloTM and XoFloTM
products.
ABOUT PAISLEY LABORATORIES: Paisley Laboratories is
headquartered in La Costa,
California with laboratories nearby and a cGMP manufacturing
facility in Florida. They have
extensive intellectual property surrounding proprietary methods for
obtaining concentrated growth factors and exosomes from human
mesenchymal stem cells and their utility.
View original
content:http://www.prnewswire.com/news-releases/direct-biologics-llc-has-acquired-paisley-laboratories-llc-300752524.html
SOURCE Direct Biologics